media – Page 6 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Just now! The National Medical Insurance Administration and the Ministry of Finance issued a document to solve the difficulty of collecting payments!

On November 11, the “Notice of the Office of the National Medical Insurance Administration and the General Office of the Ministry of Finance on Doing a Good Job in Prepayment of Medical Insurance Funds” (full text attached at the end of the article) was officially released. According to the notice, in principle, the prepayment is based on the average monthly expenditure of the relevant medical insurance funds in the previous one to three years, and the basic scale is determined, and adjusted in combination with the annual comprehensive evaluation and credit evaluation of designated medical institutions. The prepayment scale is about 1 month. The document clearly stipulates that medical insurance prepayments shall not be used for non-medical expenses such as medical institution infrastructure investment, daily operation, and debt repayment. The special prepayment of medical insurance funds for centralized volume procurement of drugs and medical consumables shall be implemented in accordance ...
- Source: drugdu
- 49
- November 13, 2024
1.82 billion, “China Resources” adds another member

On November 8, China Resources Boya Bio’s official website announced that “China Resources Boya Bio and Green Cross (China) meeting and work docking meeting were successfully held”. Two days ago (November 6), China Resources Boya Bio completed the acquisition of 100% equity of Green Cross (Hong Kong) and began to include it in the scope of consolidated financial statements. So far, “China Resources” has officially made another move in the blood products sector. In July this year, China Resources Boya Bio agreed to transfer 100% equity of Green Cross (Hong Kong) with its own funds of 1.82 billion yuan, thereby indirectly acquiring the domestic blood products entity Green Cross (China) (for details, please refer to the previous article “Spending 1.82 billion! China Resources Group takes action again”). As the blood products platform of China Resources’ big health sector, China Resources Boya Bio’s contribution to China Resources Pharmaceutical’s performance cannot be ...
- Source: drugdu
- 47
- November 13, 2024
The employee stock ownership plan of the pharmaceutical leader has been lifted

On November 6, 2024, Hengrui Medicine, the “pharmaceutical leader” listed on the A-share market, announced that the second lock-up period of the company’s 2022 employee stock ownership plan will expire on November 7, 2024. After the expiration, the management committee will dispose of the rights and interests in accordance with the provisions of this employee stock ownership plan based on the arrangements of this employee stock ownership plan, market conditions and other comprehensive factors. This also means that hundreds of core employees of Hengrui Medicine will share a big “red envelope” again. Hengrui’s employee stock ownership plan was established in November 2022. The shares came from the company’s repurchase special securities account, totaling 12 million shares; according to the disclosed information at the time, the transfer price was only 4.97 yuan/share. As of November 6, 2024, Hengrui Medicine’s closing price was 48.75 yuan/share, which is nearly 10 times the original ...
- Source: drugdu
- 40
- November 13, 2024
Consumer healthcare leaders collectively stagnate

The third quarter of 2024 is an epoch-making watershed. An unprecedented large-scale stagnation has occurred in the consumer healthcare field. From medical beauty, ophthalmology, dentistry, pharmaceutical retail, branded Chinese medicine, growth hormone to self-funded vaccines, the leaders in various segments have become old and collectively lost their growth potential. The mismatch between business model, product structure and consumer market is one of the reasons for the predicament, but it is so difficult for a company to get out of the path dependence that created its former glory. Now there are two problems. First, how does the market value companies that have lost their growth but are still profitable? When a company stops growing, the only investment attraction is high dividends, but consumer healthcare companies are almost all stingy. Second, when will consumption pick up? When will the consumption inflection point come? Japan’s situation from 1990 to 1997 is inspiring. Consumption ...
- Source: drugdu
- 46
- November 13, 2024
【EXPERT Q&A】What is the concept of GMP certification? What is the connection between GMP and FDA?

Drugdu.com expert’s response: Ⅰ. GMP Certification Concept GMP, an acronym for GOOD MANUFACTURING PRACTICE, signifies “Good Manufacturing Practices” in Chinese. The World Health Organization defines GMP as a regulation guiding the production and quality management of food, pharmaceuticals, and medical products. GMP is a mandatory standard applicable to industries such as pharmaceuticals and food, requiring enterprises to meet hygiene quality requirements in terms of raw materials, personnel, facilities and equipment, production processes, packaging and transportation, and quality control, in accordance with relevant national regulations. It forms a set of operable operational norms to help enterprises improve their hygiene environment and promptly identify and rectify issues in the production process. GMP mandates that pharmaceutical and food production enterprises possess good production equipment, reasonable production processes, comprehensive quality management, and rigorous testing systems to ensure that the final product quality (including food safety and hygiene) meets regulatory requirements. In the pharmaceutical production ...
- Source: drugdu
- 52
- November 13, 2024
Pfizer increases investment in innovative drug research and development in China

On the morning of November 6th, at the 7th China International Import Expo (CIIE), Jean Christophe Pointeau, President of Pfizer China, a multinational pharmaceutical giant, revealed that the company will launch the “Pfizer China 2030 Strategy” during this year’s CIIE. From 2025 to 2030, Pfizer will invest 1 billion US dollars, about 7.5 billion yuan, in China. Pfizer will continue to invest in accelerating innovation, improving diagnostic capabilities and treatment standards, and promoting the development of the local biotechnology industry to support the ‘Healthy China 2030’ initiative. This strategy is based on three pillars: firstly, accelerating the launch of innovative drugs and introducing breakthrough innovative products more quickly; The second is to continue to improve diagnostic capabilities and treatment standards, especially in rural areas, and promote the connection between first-class hospitals and rural areas; The third is to promote the development of the local biotechnology industry. As an important part ...
- Source: drugdu
- 53
- November 12, 2024
Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 48
- November 12, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 49
- November 12, 2024
The “trust crack” of the first brother of early cancer screening

In the past ten years, Precision Science’s colorectal cancer early screening product Cologuard has told an open growth story. The continuous growth has also made Cologuard synonymous with colon cancer screening. However, after more than ten years of growth, can Cologuard continue? There are many affirmative voices, but wavering emotions are also beginning to appear. On November 6, Precision Science handed in a good third-quarter report. In the third quarter, Precision Science’s total revenue reached US$707 million, a year-on-year increase of 13%; among them, the core screening business revenue was US$545 million, a year-on-year growth rate of 15%. Although the growth rate is still considerable, Precision Science has lowered its full-year revenue guidance. The scale of screening business revenue is US$78 million less than expected, and the full-year revenue cap of this business is US$2.095 billion. This means that there will be a decline in the fourth quarter compared with ...
- Source: drugdu
- 46
- November 12, 2024
The National Medical Insurance Bureau notified that the prices of many types of inspection items have been reduced.

Recently, the National Medical Insurance Bureau has uniformly deployed various provinces to carry out standardized governance of medical service prices, promote reasonable price reductions for some large-volume and high-priced inspection and testing items, further reduce the burden on patients to see doctors, and promote the relative balance of inspection and testing prices among provinces. Which items will be focused on? At present, there are more than 2,000 inspection and testing items in various provinces across the country. Affected by factors such as information barriers, the prices of some items vary greatly in different provinces. For example, the thromboelastogram test, which is a test used to evaluate coagulation function, costs 360 yuan per time in some places and only 100 yuan per time in some places, which is several times different. The reason behind this is mainly that the procurement costs of some inspection reagents or equipment are inflated, resulting in ...
- Source: drugdu
- 44
- November 12, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.